[go: up one dir, main page]

AU2001244292A1 - Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries - Google Patents

Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries

Info

Publication number
AU2001244292A1
AU2001244292A1 AU2001244292A AU2001244292A AU2001244292A1 AU 2001244292 A1 AU2001244292 A1 AU 2001244292A1 AU 2001244292 A AU2001244292 A AU 2001244292A AU 2001244292 A AU2001244292 A AU 2001244292A AU 2001244292 A1 AU2001244292 A1 AU 2001244292A1
Authority
AU
Australia
Prior art keywords
expression
treating
function
cell cycle
protein involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001244292A
Other versions
AU2001244292B2 (en
Inventor
Yehezkel Ben-Ari
Pauline Cavelier
Michel Khrestchatisky
Laurent Meijer
Serge Timsit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0003673A external-priority patent/FR2806626B1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2001244292A1 publication Critical patent/AU2001244292A1/en
Application granted granted Critical
Publication of AU2001244292B2 publication Critical patent/AU2001244292B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001244292A 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries Ceased AU2001244292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/3673 2000-03-22
FR0003673A FR2806626B1 (en) 2000-03-22 2000-03-22 USE OF MODULATING SUBSTANCES FOR THE EXPRESSION OR FUNCTION OF A PROTEIN INVOLVED IN THE CELL CYCLE FOR THE TREATMENT OR PREVENTION OF ACUTE NEURAL INJURIES
PCT/FR2001/000850 WO2001070231A2 (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries

Publications (2)

Publication Number Publication Date
AU2001244292A1 true AU2001244292A1 (en) 2001-12-13
AU2001244292B2 AU2001244292B2 (en) 2005-09-22

Family

ID=8848391

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4429201A Pending AU4429201A (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
AU2001244292A Ceased AU2001244292B2 (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU4429201A Pending AU4429201A (en) 2000-03-22 2001-03-21 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries

Country Status (9)

Country Link
US (1) US20030060397A1 (en)
EP (1) EP1265602A2 (en)
JP (1) JP2003527428A (en)
AU (2) AU4429201A (en)
CA (1) CA2403714A1 (en)
FR (1) FR2806626B1 (en)
IL (1) IL151800A0 (en)
WO (1) WO2001070231A2 (en)
ZA (1) ZA200207448B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2899107B1 (en) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle USE OF (S) -ROSCOVITINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
GB201217621D0 (en) * 2012-10-02 2012-11-14 Univ Leuven Kath Anticonvulsant activity of gsk-3b inhibitors
CN107847523B (en) 2015-04-07 2022-03-11 J·大卫格莱斯顿学会(根据J·大卫格莱斯顿意愿建立的遗嘱信托) Method for inducing cell division of postmitotic cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323185T2 (en) * 1992-02-24 1999-07-08 Smithkline Beecham Corp., Philadelphia, Pa. 19101 PROTEIN KINASE C INHIBITOR
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
GB9521322D0 (en) * 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
FR2741881B1 (en) * 1995-12-01 1999-07-30 Centre Nat Rech Scient NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
EP1003519A4 (en) * 1997-03-03 2003-08-20 Univ Texas SUPPRESSION OF CYCLINE KINASE 2 ACTIVITY TO PREVENT AND TREAT VIRAL DNA INFECTIONS
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP0911634A1 (en) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmaceutical uses of CDK-2 regulators
ZA9811178B (en) * 1997-12-13 2000-06-07 Bristol Myers Squibb Co Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
NZ506234A (en) * 1998-02-26 2003-05-30 Aventis Pharma Inc 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines, pharmaceuticals thereof and their use for inhibiting cdk-2
FR2804959B1 (en) * 2000-02-15 2006-04-28 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
ATE301123T1 (en) * 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES

Similar Documents

Publication Publication Date Title
ZA989249B (en) Heteroaromatic compounds and their use in medicine.
DE69930410D1 (en) INFRARED FORMATION FOR THE DETECTION OF INGREDIENTS IN BODY CARE PRODUCTS
HUP0104296A3 (en) Cross-linked hyaluronic acids, uses thereof and biological substances containing them
AR011565A3 (en) A MOISTURIZING, LIQUID AND AQUEOUS COMPOSITION
DE69838337D1 (en) AMPHOLITIC POLYMERS FOR USE IN BODY CARE PRODUCTS
AU4058200A (en) Treating body tissue by applying energy and substances
DE69804659D1 (en) 21-HYDRO-6,19-OXIDOPROGESTERONE (21OH-60P) AND THE USE THEREOF AS A MEDICINE FOR TREATING GLUCOCORTICO excess
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
DE69512277D1 (en) DEFORMABLE CONTAINER FOR INJECTING MEDICINAL OR COSMETIC AGENTS
AU2001285942A1 (en) Liquid oligosiloxane containing sulphur and the use thereof in rubber mixtures
AU2837301A (en) Use of polymeric material in the treatment of hard surfaces
HUP0103117A3 (en) Tnf-derived peptides for use in treating oedema
AU8803398A (en) Photochromatic compounds, process for their preparation and their use in polymeric materials
AU2001244292A1 (en) Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
AU757752C (en) Benzylidene pyrazolones, production and use thereof
GB2361231B (en) Cosmetic container and cartridge for cosmetic container
IL151800A0 (en) Use of substances modulating the expression of the function of a protein involved in the cell cycle for treating or preventing acute neural injuries
EE200200124A (en) Container closure process and associated closure means
AU2002218346A1 (en) Insoluble organic uv filters and cosmetic use thereof
DE69712313D1 (en) ABSORBENT DISPOSABLE PRODUCT WITH STRIPE CLOSURES
EP1101421A4 (en) Cosmetic container and cartridge for cosmetic container
DE59809730D1 (en) BAG OR CONTAINER
PL338123A1 (en) 6-pyrrolydin-2-ylpyridines, their production and application in therapy
EP1032266A4 (en) Use of delta5-androstene-3beta-ol-7,17-dione in the treatment of arthritis